MA50899B1 - Compounds useful for cdk7 inhibition - Google Patents
Compounds useful for cdk7 inhibitionInfo
- Publication number
- MA50899B1 MA50899B1 MA50899A MA50899A MA50899B1 MA 50899 B1 MA50899 B1 MA 50899B1 MA 50899 A MA50899 A MA 50899A MA 50899 A MA50899 A MA 50899A MA 50899 B1 MA50899 B1 MA 50899B1
- Authority
- MA
- Morocco
- Prior art keywords
- compounds useful
- cdk7 inhibition
- cdk7
- inhibition
- novel
- Prior art date
Links
- 101150059448 cdk7 gene Proteins 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title 1
- 230000005764 inhibitory process Effects 0.000 title 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La présente invention concerne de nouveaux inhibiteurs de cdk7 et des compositions pharmaceutiques associées : (i), ou un sel pharmaceutiquement acceptable de ceux-ci.The present invention relates to novel cdk7 inhibitors and related pharmaceutical compositions: (i), or a pharmaceutically acceptable salt thereof.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17382778 | 2017-11-16 | ||
| PCT/US2018/060025 WO2019099298A1 (en) | 2017-11-16 | 2018-11-09 | Compounds useful for inhibiting cdk7 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA50899A MA50899A (en) | 2020-09-23 |
| MA50899B1 true MA50899B1 (en) | 2022-10-31 |
Family
ID=60484312
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA50899A MA50899B1 (en) | 2017-11-16 | 2018-11-09 | Compounds useful for cdk7 inhibition |
Country Status (2)
| Country | Link |
|---|---|
| AR (1) | AR113817A1 (en) |
| MA (1) | MA50899B1 (en) |
-
2018
- 2018-10-31 AR ARP180103173A patent/AR113817A1/en unknown
- 2018-11-09 MA MA50899A patent/MA50899B1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MA50899A (en) | 2020-09-23 |
| AR113817A1 (en) | 2020-06-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JOP20200122A1 (en) | Compounds useful for inhibiting cdk7 | |
| MA43169B1 (en) | Heterocyclic compounds as pi3k-gamma inhibitors | |
| GEP20237561B (en) | Protein tyrosine phosphatase inhibitors | |
| MA51204B1 (en) | Pharmaceutical forms comprising a plasma kallikrein inhibitor | |
| EA202193015A1 (en) | CDK INHIBITORS | |
| EA201691401A1 (en) | INDASOLIC COMPOUNDS AS IRAK4 INHIBITORS | |
| MA42339A1 (en) | Farnesoid Receptor Modulators x | |
| EA201991884A2 (en) | G12C KRAS INHIBITORS | |
| MA46337A (en) | PYRIDINE COMPOUND | |
| MA42776B1 (en) | Compounds useful for inhibiting t-ror | |
| JOP20190233A1 (en) | Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase | |
| EA201992542A1 (en) | PHARMACEUTICAL COMPOSITION FOR LOCAL USE CONTAINING, AT LEAST, AMITRIPTILINE FOR THE TREATMENT OF PERIPHERAL NEUROPATHIC PAIN | |
| MY202753A (en) | Griseofulvin compound and pharmaceutical use thereof | |
| MX376202B (en) | Condensed thiophene derivatives useful as napi-iib inhibitors | |
| MA40366A (en) | TETRAHYDROQUINOLINE DERIVATIVES AS BROMODOMA INHIBITORS | |
| MA43913B1 (en) | Positive allosteric modulators of the m1 muscarinic receptor | |
| MA46039B1 (en) | Triazolopyrazinone derivative useful as an inhibitor of human pde1 | |
| MA41311B1 (en) | cgrp antagonist peptides | |
| PH12021550258A1 (en) | Cdk8/19 inhibitors | |
| MY207182A (en) | Pharmaceutical composition comprising benzimidazole derivative compound | |
| MA50899B1 (en) | Compounds useful for cdk7 inhibition | |
| EA202190339A1 (en) | PYRIDOPYRIMIDINES AS INHIBITORS OF H4-HISTAMINE RECEPTORS | |
| MA44383B1 (en) | A derivative of 4- (3-pyrazolylamino) -benzimidazole as a jak1 inhibitor for the treatment of cancer | |
| WO2020065090A3 (en) | 5-ht7 antagonist for the treatment of dementia-associated tauopathies | |
| MX394259B (en) | Bruton's Tyrosine Kinase (BTK) Inhibitor Compounds |